Results 201 to 210 of about 1,411,652 (360)

Potential Survival Benefit of Adjuvant Chemotherapy in Stage IV Intrahepatic Cholangiocarcinoma: A Multicenter, Stage‐Stratified Analysis

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This multicenter study suggests that adjuvant chemotherapy may improve survival in stage IV intrahepatic cholangiocarcinoma after resection, with S‐1 showing a potential survival advantage. ABSTRACT Background The survival benefit of adjuvant chemotherapy (AC) in intrahepatic cholangiocarcinoma (ICC) remains uncertain, particularly in advanced‐stage ...
Hisashi Kosaka   +9 more
wiley   +1 more source

Combination of Ethoxybenzyl‐Diethylenetriamine Pentaacetic Acid‐Enhanced Magnetic Resonance Imaging and a Serum Biomarker Is Useful in the Diagnosis of Hepatic Sinusoidal Disorder After Chemotherapy Treatment

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ROC analyses of APRI score, EOB‐MRI, and a combination of EOB‐MRI and APRI score for blue liver. ABSTRACT Aim Sinusoidal obstruction syndrome (SOS), also known as “blue liver (BL),” is a common hepatic injury following oxaliplatin‐based chemotherapy in patients with colorectal liver metastases (CRLM).
Tomonari Shimagaki   +7 more
wiley   +1 more source

Unexpectedly High Incidence of Immune‐Related Adverse Events in Gastric Cancer Patients Who Received Conversion Surgery After Nivolumab‐Including Chemotherapy

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Nivolumab‐including chemotherapy (nivo‐CTX) for stage IV gastric cancer (GC) may increase the chance of conversion surgery but risk of immune‐related adverse events (irAEs) during perioperative period remains unclear. Methods We examined irAEs in 36 patients with marginally resectable GC who received nivo‐CTX followed by surgery ...
Masashi Nishino   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy